155 related articles for article (PubMed ID: 38049358)
1. Use of Therapeutic Apheresis methods in ICU.
Zikou X; Vaia D; Vasiliki P; Panagiotis C; Stavros A
Transfus Apher Sci; 2024 Feb; 63(1):103853. PubMed ID: 38049358
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Plasma Exchange in Tehran Between 2011 and 2014.
Chegini A; Moghadami M; Maghary AH
Ther Apher Dial; 2020 Apr; 24(2):230-234. PubMed ID: 31177634
[TBL] [Abstract][Full Text] [Related]
3. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.
Bandarenko N; Brecher ME
J Clin Apher; 1998; 13(3):133-41. PubMed ID: 9828024
[TBL] [Abstract][Full Text] [Related]
4. A two-year analysis of therapeutic apheresis practices in a tertiary center: are we chasing the new indications?
Ersan S; Ersan G
Hippokratia; 2018; 22(4):167-172. PubMed ID: 31695303
[TBL] [Abstract][Full Text] [Related]
5. Principles of Therapeutic Apheresis in Neurological Disease.
Strasser E
Transfus Med Hemother; 2023 Apr; 50(2):88-97. PubMed ID: 37066058
[TBL] [Abstract][Full Text] [Related]
6. Medications and therapeutic apheresis procedures: are we doing our best?
Ibrahim RB; Balogun RA
J Clin Apher; 2013 Feb; 28(1):73-7. PubMed ID: 23420597
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of pediatric plasma apheresis in intensive care settings.
Haque A; Sher G; Hoda M; Moiz B
Ther Apher Dial; 2014 Oct; 18(5):497-501. PubMed ID: 24674133
[TBL] [Abstract][Full Text] [Related]
10. Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
Martin SD; McGinnis E; Smith TW
Am J Clin Pathol; 2021 Nov; 156(6):1103-1112. PubMed ID: 34160013
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal plasma treatment in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: a review.
Bosch T; Wendler T
Ther Apher; 2001 Jun; 5(3):182-5. PubMed ID: 11467754
[TBL] [Abstract][Full Text] [Related]
12. Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange: When It Works and When It Does Not.
Mehmood T; Taylor M; Winters JL
Hematol Oncol Clin North Am; 2016 Jun; 30(3):679-94. PubMed ID: 27113004
[TBL] [Abstract][Full Text] [Related]
13. Therapeutical plasma exchange for thrombotic thrombocytopenic purpura in the emergency department: A single center experience.
Li XM; Mo XY; Huang GQ; Zhang FJ
Am J Emerg Med; 2021 Aug; 46():556-559. PubMed ID: 33214018
[TBL] [Abstract][Full Text] [Related]
14. Apheresis and the thrombotic thrombocytopenic purpura syndrome: current advances in diagnosis, pathophysiology, and management.
Brailey LL; Brecher ME; Bandarenko N
Ther Apher; 1999 Feb; 3(1):20-4. PubMed ID: 10079801
[TBL] [Abstract][Full Text] [Related]
15. Applications of Therapeutic Apheresis in Patients with Malignant Disease.
Pineda AA; Vamvakas EC
Oncologist; 1997; 2(2):94-103. PubMed ID: 10388036
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and limitation of apheresis therapy in critical care.
Hirasawa H; Sugai T; Oda S; Shiga H; Matsuda K; Ueno H; Sadahiro T
Ther Apher; 1997 Aug; 1(3):228-32. PubMed ID: 10225744
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Pham HP; Schwartz J
Presse Med; 2019 Nov; 48(11 Pt 2):338-346. PubMed ID: 31679897
[TBL] [Abstract][Full Text] [Related]
18. Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Soucemarianadin M; Benhamou Y; Delmas Y; Pichereau C; Maury E; Pène F; Halimi JM; Presne C; Thouret JM; Veyradier A; Coppo P
Eur J Haematol; 2016 Aug; 97(2):183-91. PubMed ID: 26608617
[TBL] [Abstract][Full Text] [Related]
19. Taking therapeutic apheresis services to patients in South Africa: An eight year review of SANBS mobile therapeutic apheresis service, 2013-2020.
Poole C; Strydom C; van der Berg K; Vrielink H
Transfus Apher Sci; 2021 Jun; 60(3):103167. PubMed ID: 34116933
[TBL] [Abstract][Full Text] [Related]
20. How we approach an acquired thrombotic thrombocytopenic purpura patient.
Raval JS; Mazepa MA; Brecher ME; Park YA
Transfusion; 2014 Oct; 54(10):2375-82. PubMed ID: 25070750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
